Cargando…

Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease

BACKGROUND: The assessment of fibrosis and inflammatory activity is essential to identify patients with non-alcoholic fatty liver disease (NAFLD) at risk for progressive disease. Serum markers and ultrasound-based methods can replace liver biopsy for fibrosis staging, whereas non-invasive characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlas, Thomas, Weise, Lara, Kuhn, Stephanie, Krenzien, Felix, Mehdorn, Matthias, Petroff, David, Linder, Nicolas, Schaudinn, Alexander, Busse, Harald, Keim, Volker, Pratschke, Johann, Wiegand, Johannes, Splith, Katrin, Schmelzle, Moritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437653/
https://www.ncbi.nlm.nih.gov/pubmed/28521774
http://dx.doi.org/10.1186/s12967-017-1208-6
_version_ 1783237633350041600
author Karlas, Thomas
Weise, Lara
Kuhn, Stephanie
Krenzien, Felix
Mehdorn, Matthias
Petroff, David
Linder, Nicolas
Schaudinn, Alexander
Busse, Harald
Keim, Volker
Pratschke, Johann
Wiegand, Johannes
Splith, Katrin
Schmelzle, Moritz
author_facet Karlas, Thomas
Weise, Lara
Kuhn, Stephanie
Krenzien, Felix
Mehdorn, Matthias
Petroff, David
Linder, Nicolas
Schaudinn, Alexander
Busse, Harald
Keim, Volker
Pratschke, Johann
Wiegand, Johannes
Splith, Katrin
Schmelzle, Moritz
author_sort Karlas, Thomas
collection PubMed
description BACKGROUND: The assessment of fibrosis and inflammatory activity is essential to identify patients with non-alcoholic fatty liver disease (NAFLD) at risk for progressive disease. Serum markers and ultrasound-based methods can replace liver biopsy for fibrosis staging, whereas non-invasive characterization of inflammatory activity remains a clinical challenge. Cell-free DNA (cfDNA) is a novel non-invasive biomarker for assessing cellular inflammation and cell death, which has not been evaluated in NAFLD. METHODS: Patients and healthy controls from two previous studies were included. NAFLD disease activity and severity were non-invasively characterized by liver stiffness measurement (transient elastography, TE) including steatosis assessment with controlled attenuation parameter (CAP), single-proton magnetic resonance spectroscopy ((1)H-MRS) for determination of hepatic fat fraction, aminotransferases and serum ferritin. cfDNA levels (90 and 222 bp fragments) were analyzed using quantitative real-time PCR. RESULTS: Fifty-eight NAFLD patients (age 62 ± 11 years, BMI 28.2 ± 3.5 kg/m(2)) and 13 healthy controls (age 38 ± 12 years, BMI 22.4 ± 2.1 kg/m(2)) were included. 90 bp cfDNA levels were significantly higher in NAFLD patients compared to healthy controls: 3.7 (1.3–23.1) vs. 2.9 (1.4–4.1) ng/mL (p = 0.014). In the NAFLD cohort, circulating cfDNA correlated significantly with disease activity and severity, especially in patients with elevated liver stiffness (n = 13, 22%) compared to cases with TE values ≤7 kPa: cf90 bp 6.05 (2.41–23.13) vs. 3.16 (1.29–7.31) ng/mL (p < 0.001), and cf222 bp 14.41 (9.27–22.90) vs. 11.32 (6.05–18.28) ng/mL (p = 0.0041). CONCLUSIONS: Cell-free DNA plasma concentration correlates with established non-invasive markers of NAFLD activity and severity. Therefore, cfDNA should be further evaluated as biomarker for identifying patients at risk for progressive NAFLD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1208-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5437653
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54376532017-05-22 Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease Karlas, Thomas Weise, Lara Kuhn, Stephanie Krenzien, Felix Mehdorn, Matthias Petroff, David Linder, Nicolas Schaudinn, Alexander Busse, Harald Keim, Volker Pratschke, Johann Wiegand, Johannes Splith, Katrin Schmelzle, Moritz J Transl Med Research BACKGROUND: The assessment of fibrosis and inflammatory activity is essential to identify patients with non-alcoholic fatty liver disease (NAFLD) at risk for progressive disease. Serum markers and ultrasound-based methods can replace liver biopsy for fibrosis staging, whereas non-invasive characterization of inflammatory activity remains a clinical challenge. Cell-free DNA (cfDNA) is a novel non-invasive biomarker for assessing cellular inflammation and cell death, which has not been evaluated in NAFLD. METHODS: Patients and healthy controls from two previous studies were included. NAFLD disease activity and severity were non-invasively characterized by liver stiffness measurement (transient elastography, TE) including steatosis assessment with controlled attenuation parameter (CAP), single-proton magnetic resonance spectroscopy ((1)H-MRS) for determination of hepatic fat fraction, aminotransferases and serum ferritin. cfDNA levels (90 and 222 bp fragments) were analyzed using quantitative real-time PCR. RESULTS: Fifty-eight NAFLD patients (age 62 ± 11 years, BMI 28.2 ± 3.5 kg/m(2)) and 13 healthy controls (age 38 ± 12 years, BMI 22.4 ± 2.1 kg/m(2)) were included. 90 bp cfDNA levels were significantly higher in NAFLD patients compared to healthy controls: 3.7 (1.3–23.1) vs. 2.9 (1.4–4.1) ng/mL (p = 0.014). In the NAFLD cohort, circulating cfDNA correlated significantly with disease activity and severity, especially in patients with elevated liver stiffness (n = 13, 22%) compared to cases with TE values ≤7 kPa: cf90 bp 6.05 (2.41–23.13) vs. 3.16 (1.29–7.31) ng/mL (p < 0.001), and cf222 bp 14.41 (9.27–22.90) vs. 11.32 (6.05–18.28) ng/mL (p = 0.0041). CONCLUSIONS: Cell-free DNA plasma concentration correlates with established non-invasive markers of NAFLD activity and severity. Therefore, cfDNA should be further evaluated as biomarker for identifying patients at risk for progressive NAFLD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1208-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-19 /pmc/articles/PMC5437653/ /pubmed/28521774 http://dx.doi.org/10.1186/s12967-017-1208-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Karlas, Thomas
Weise, Lara
Kuhn, Stephanie
Krenzien, Felix
Mehdorn, Matthias
Petroff, David
Linder, Nicolas
Schaudinn, Alexander
Busse, Harald
Keim, Volker
Pratschke, Johann
Wiegand, Johannes
Splith, Katrin
Schmelzle, Moritz
Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
title Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
title_full Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
title_fullStr Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
title_full_unstemmed Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
title_short Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
title_sort correlation of cell-free dna plasma concentration with severity of non-alcoholic fatty liver disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437653/
https://www.ncbi.nlm.nih.gov/pubmed/28521774
http://dx.doi.org/10.1186/s12967-017-1208-6
work_keys_str_mv AT karlasthomas correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT weiselara correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT kuhnstephanie correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT krenzienfelix correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT mehdornmatthias correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT petroffdavid correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT lindernicolas correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT schaudinnalexander correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT busseharald correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT keimvolker correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT pratschkejohann correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT wiegandjohannes correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT splithkatrin correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease
AT schmelzlemoritz correlationofcellfreednaplasmaconcentrationwithseverityofnonalcoholicfattyliverdisease